vs
Orthofix Medical Inc.（OFIX）与SHOE CARNIVAL INC（SCVL）财务数据对比。点击上方公司名可切换其他公司
SHOE CARNIVAL INC的季度营收约是Orthofix Medical Inc.的1.4倍（$297.2M vs $219.9M），SHOE CARNIVAL INC净利率更高（4.9% vs -1.0%，领先5.9%），Orthofix Medical Inc.同比增速更快（2.0% vs -3.2%），SHOE CARNIVAL INC自由现金流更多（$19.7M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 3.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Shoe Carnival Inc是一家美国家庭鞋类零售商，目前在美国中西部、南部、东南部地区以及波多黎各共开设了429家门店。该公司由大卫·拉塞尔于1978年创立，截至2025年，其总部位于南卡罗来纳州福特米尔。
OFIX vs SCVL — 直观对比
营收规模更大
SCVL
是对方的1.4倍
$219.9M
营收增速更快
OFIX
高出5.1%
-3.2%
净利率更高
SCVL
高出5.9%
-1.0%
自由现金流更多
SCVL
多$2.9M
$16.8M
两年增速更快
OFIX
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $297.2M |
| 净利润 | $-2.2M | $14.6M |
| 毛利率 | 71.1% | 37.6% |
| 营业利润率 | 0.2% | 6.3% |
| 净利率 | -1.0% | 4.9% |
| 营收同比 | 2.0% | -3.2% |
| 净利润同比 | 92.4% | -23.9% |
| 每股收益（稀释后） | $-0.05 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXSCVL
| Q4 25 | $219.9M | $297.2M | ||
| Q3 25 | $205.6M | $306.4M | ||
| Q2 25 | $203.1M | $277.7M | ||
| Q1 25 | $193.6M | $262.9M | ||
| Q4 24 | $215.7M | $306.9M | ||
| Q3 24 | $196.6M | $332.7M | ||
| Q2 24 | $198.6M | $300.4M | ||
| Q1 24 | $188.6M | $280.2M |
净利润OFIXSCVL
| Q4 25 | $-2.2M | $14.6M | ||
| Q3 25 | $-22.8M | $19.2M | ||
| Q2 25 | $-14.1M | $9.3M | ||
| Q1 25 | $-53.1M | $14.7M | ||
| Q4 24 | $-29.1M | $19.2M | ||
| Q3 24 | $-27.4M | $22.6M | ||
| Q2 24 | $-33.4M | $17.3M | ||
| Q1 24 | $-36.0M | $15.5M |
毛利率OFIXSCVL
| Q4 25 | 71.1% | 37.6% | ||
| Q3 25 | 72.2% | 38.8% | ||
| Q2 25 | 68.7% | 34.5% | ||
| Q1 25 | 62.8% | 34.9% | ||
| Q4 24 | 69.0% | 36.0% | ||
| Q3 24 | 68.7% | 36.1% | ||
| Q2 24 | 67.8% | 35.6% | ||
| Q1 24 | 67.5% | 35.6% |
营业利润率OFIXSCVL
| Q4 25 | 0.2% | 6.3% | ||
| Q3 25 | -8.3% | 8.2% | ||
| Q2 25 | -7.9% | 4.3% | ||
| Q1 25 | -25.2% | 5.3% | ||
| Q4 24 | -5.3% | 8.0% | ||
| Q3 24 | -9.6% | 9.0% | ||
| Q2 24 | -12.5% | 7.5% | ||
| Q1 24 | -15.6% | 7.1% |
净利率OFIXSCVL
| Q4 25 | -1.0% | 4.9% | ||
| Q3 25 | -11.1% | 6.3% | ||
| Q2 25 | -6.9% | 3.4% | ||
| Q1 25 | -27.4% | 5.6% | ||
| Q4 24 | -13.5% | 6.3% | ||
| Q3 24 | -13.9% | 6.8% | ||
| Q2 24 | -16.8% | 5.8% | ||
| Q1 24 | -19.1% | 5.5% |
每股收益（稀释后）OFIXSCVL
| Q4 25 | $-0.05 | $0.53 | ||
| Q3 25 | $-0.57 | $0.70 | ||
| Q2 25 | $-0.36 | $0.34 | ||
| Q1 25 | $-1.35 | $0.53 | ||
| Q4 24 | $-0.76 | $0.70 | ||
| Q3 24 | $-0.71 | $0.82 | ||
| Q2 24 | $-0.88 | $0.63 | ||
| Q1 24 | $-0.95 | $0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $107.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $683.2M |
| 总资产 | $850.6M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXSCVL
| Q4 25 | $82.0M | $107.7M | ||
| Q3 25 | $62.9M | $91.9M | ||
| Q2 25 | $65.6M | $93.0M | ||
| Q1 25 | $58.0M | $123.1M | ||
| Q4 24 | $83.2M | $91.1M | ||
| Q3 24 | $30.1M | $84.5M | ||
| Q2 24 | $26.4M | $69.5M | ||
| Q1 24 | $27.0M | $111.2M |
总债务OFIXSCVL
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXSCVL
| Q4 25 | $450.0M | $683.2M | ||
| Q3 25 | $442.5M | $670.7M | ||
| Q2 25 | $458.3M | $653.6M | ||
| Q1 25 | $458.3M | $649.0M | ||
| Q4 24 | $503.1M | $635.7M | ||
| Q3 24 | $525.9M | $618.5M | ||
| Q2 24 | $546.0M | $597.8M | ||
| Q1 24 | $570.3M | $583.4M |
总资产OFIXSCVL
| Q4 25 | $850.6M | $1.2B | ||
| Q3 25 | $832.6M | $1.2B | ||
| Q2 25 | $837.2M | $1.1B | ||
| Q1 25 | $823.1M | $1.1B | ||
| Q4 24 | $893.3M | $1.1B | ||
| Q3 24 | $867.9M | $1.1B | ||
| Q2 24 | $882.0M | $1.1B | ||
| Q1 24 | $906.0M | $1.0B |
负债/权益比OFIXSCVL
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $33.6M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $19.7M |
| 自由现金流率自由现金流/营收 | 7.6% | 6.6% |
| 资本支出强度资本支出/营收 | 4.9% | 4.7% |
| 现金转化率经营现金流/净利润 | — | 2.30× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $35.1M |
8季度趋势，按日历期对齐
经营现金流OFIXSCVL
| Q4 25 | $27.7M | $33.6M | ||
| Q3 25 | $12.4M | $13.3M | ||
| Q2 25 | $11.6M | $-9.6M | ||
| Q1 25 | $-18.4M | $44.5M | ||
| Q4 24 | $23.7M | $17.3M | ||
| Q3 24 | $11.7M | $23.7M | ||
| Q2 24 | $9.0M | $17.1M | ||
| Q1 24 | $-18.6M | $53.4M |
自由现金流OFIXSCVL
| Q4 25 | $16.8M | $19.7M | ||
| Q3 25 | $2.5M | $2.2M | ||
| Q2 25 | $4.5M | $-23.0M | ||
| Q1 25 | $-25.1M | $36.2M | ||
| Q4 24 | $15.2M | $8.3M | ||
| Q3 24 | $6.3M | $18.2M | ||
| Q2 24 | $-360.0K | $6.9M | ||
| Q1 24 | $-29.1M | $40.7M |
自由现金流率OFIXSCVL
| Q4 25 | 7.6% | 6.6% | ||
| Q3 25 | 1.2% | 0.7% | ||
| Q2 25 | 2.2% | -8.3% | ||
| Q1 25 | -13.0% | 13.8% | ||
| Q4 24 | 7.0% | 2.7% | ||
| Q3 24 | 3.2% | 5.5% | ||
| Q2 24 | -0.2% | 2.3% | ||
| Q1 24 | -15.4% | 14.5% |
资本支出强度OFIXSCVL
| Q4 25 | 4.9% | 4.7% | ||
| Q3 25 | 4.8% | 3.6% | ||
| Q2 25 | 3.5% | 4.8% | ||
| Q1 25 | 3.5% | 3.2% | ||
| Q4 24 | 4.0% | 3.0% | ||
| Q3 24 | 2.7% | 1.7% | ||
| Q2 24 | 4.7% | 3.4% | ||
| Q1 24 | 5.6% | 4.5% |
现金转化率OFIXSCVL
| Q4 25 | — | 2.30× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | -1.03× | ||
| Q1 25 | — | 3.04× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 1.05× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | — | 3.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
SCVL
暂无分部数据
